Melanoma Condition Center Debuts

Published Online: Thursday, September 13, 2012
Follow Pharmacy_Times:
This month, we introduce a new condition center on www.PharmacyTimes.com covering melanoma, which accounts for approximately 5% of skin cancers, but is responsible for 3 times as many deaths as all other skin cancers combined. Once rare, melanoma’s incidence has increased along with people’s exposure to ultraviolet radiation from the sun.

Although anyone can develop melanoma, genetic factors can increase one’s risk, including having a light complexion, an inability to tan, red hair, blue eyes, or familial mole/melanoma syndrome. The first-line treatment for melanoma is surgical removal of the malignant lesion and a margin of healthy skin, but a number of medications play a role in treatment as well.

Some topics that will be covered in the melanoma condition center include:
  • A smartphone app that helps track moles that may indicate the development of melanoma
  • The discovery of a T-cell with the potential to help fight melanoma
  • The promise of combination therapy in treating melanoma


Related Articles
Taking more nutritional supplements than needed may increase a patient’s risk of cancer.
The FDA today approved a second-line treatment for metastatic colorectal cancer.
The FDA has awarded Breakthrough Therapy status to crizotinib (Xalkori) for ROS1-positive non-small cell lung cancer.
The FDA has granted Orphan Drug Designation to AstraZeneca’s selumetinib.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$